StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) bonds

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$363.12M
Long-term debt
Net debt
$157.25M
After $205.88M of cash
Implied interest rate
3.64%
FY2025 interest ÷ average debt
Interest coverage
1.1×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

Notes and loans outstanding

As tagged in Pacira BioSciences's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
Term loan A facility maturing March 2028–Mar 31, 2028$150.00M$105.31M
2.125% Convertible senior notes due May 2029
Convertible at $40 a share
2.13%May 31, 2029$287.50M$287.50M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

Credit facilities

Revolving credit lines and other committed borrowing capacity

FacilitySizeDrawn
Revolving Credit Facility–$81.00M
Wells Fargo Bank$300.00M–

See a number that looks wrong?